Hemogenyx Pharmaceuticals, the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, welcomed New York Lieutenant Governor Kathy Hochul to its labs at the SUNY Downstate Medical Center Biotech Incubator.
In addition to showing Hochul its cutting-edge facilities, Hemogenyx also briefed the Lieutenant Governor on its advanced technologies-and their potential to save lives.
The company went public last year on the London Stock Exchange, opened its first lab in Buffalo. Now its four scientists work out of two labs inside SUNY Downstate Medical Center’s Biotech Incubator.
Dr. Vladislav Sandler, CEO of Hemogenyx, said: “As a biotech company with its roots in New York, we were honored to welcome Lieutenant Governor Hochul to our labs. Having access to the high-quality facilities at SUNY Downstate has been instrumental to our success in creating a safer and more effective approach to bone marrow transplants.”
Lieutenant Governor Hochul, said: “By providing biotech businesses with state-of-the-art laboratory space and financial support in the early stages, the SUNY Downstate Biotech Incubator is setting them up with the tools they need to grow into our next entrepreneurial success stories. Hemogenyx Pharmaceuticals is one such success story, launching their business in New York State with the 43 North Startup competition and continuing to expand at SUNY Downstate’s world-class facilities.”